Published in J Exp Med on January 01, 1989
Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest (1991) 2.37
Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection. J Exp Med (1990) 1.56
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A (2010) 1.53
In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J Exp Med (1990) 1.13
Acute lethal graft-versus-host reaction induced by major histocompatibility complex class II-reactive T helper cell clones. J Exp Med (1990) 0.86
Overexpression of interleukin-2 by a recombinant herpes simplex virus type 1 attenuates pathogenicity and enhances antiviral immunity. J Virol (2002) 0.86
Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells. J Immunol (2014) 0.86
Comparison of vascular leak syndrome in mice treated with IL21 or IL2. Comp Med (2013) 0.80
Role of IL-2 in cancer immunotherapy. Oncoimmunology (2016) 0.76
T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol (1978) 28.92
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (1985) 19.41
Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol (1983) 14.36
IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol (1980) 10.30
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 8.74
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med (1984) 5.26
Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex. Proc Natl Acad Sci U S A (1983) 4.83
Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med (1986) 3.99
Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma (1984) 3.68
A glycolipid on the surface of mouse natural killer cells. Eur J Immunol (1980) 3.13
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol (1987) 3.03
Significance of Lyt phenotypes: Lyt2 antibodies block activities of T cells that recognize class 1 major histocompatibility complex antigens regardless of their function. Proc Natl Acad Sci U S A (1981) 2.95
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol (1986) 2.82
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med (1985) 2.65
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. J Immunol (1986) 2.48
Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. Relationship with tumor necrosis factor and synergism with immune interferon. J Exp Med (1985) 2.11
Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol (1987) 1.96
Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer (1986) 1.60
Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res (1984) 1.52
Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res (1986) 1.50
Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol (1987) 1.49
Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol (1986) 1.36
Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol (1985) 1.32
Flow cytometric analysis reveals the presence of asialo GM1 on the surface membrane of alloimmune cytotoxic T lymphocytes. J Immunol (1986) 1.28
Reactivity of anti-asialo GM1 serum with tumoricidal and non-tumoricidal mouse macrophages. J Leukoc Biol (1985) 1.23
Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol (1986) 1.22
Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. J Biol Response Mod (1985) 1.21
Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. J Immunol (1987) 1.13
Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection. J Exp Med (1987) 1.08
Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. J Immunol (1987) 1.07
The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol (1987) 1.07
Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells. J Immunol (1986) 1.06
Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J Immunol (1988) 1.02
Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. J Immunol (1986) 0.97
Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulations. J Immunol (1987) 0.79
Production and response to interleukin 2 in vitro and in vivo after bone marrow transplantation in mice. J Immunol (1985) 0.78
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med (1985) 2.65
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med (1981) 2.50
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol (1980) 2.20
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol (1997) 1.84
Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med (1982) 1.76
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res (1999) 1.68
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood (1996) 1.66
Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med (1986) 1.62
Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope (2000) 1.51
Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med (1986) 1.41
Oncogenic proteins as tumor antigens. Curr Opin Immunol (1996) 1.27
Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2. J Immunol (1981) 1.27
WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia (2003) 1.25
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med (1984) 1.24
In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res (1994) 1.20
Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood (2000) 1.18
Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. J Immunol (1984) 1.15
HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res (1997) 1.13
H-2 restriction of adoptive immunotherapy of advanced tumors. J Immunol (1981) 1.10
Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol (1996) 1.10
Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia. Cancer Res (1980) 1.08
T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol (1991) 1.05
Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. J Immunol (1985) 1.04
Bone marrow transplantation in patients aged 45 years and older. Blood (1986) 1.04
T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol (1991) 1.02
Lung injury induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell inflammation and activation of alveolar macrophages. J Immunol (1998) 0.99
In vivo administration of interleukin-2. Contemp Top Mol Immunol (1985) 0.99
Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res (1995) 0.98
Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. Transplantation (1982) 0.98
Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo. J Immunol (1984) 0.97
Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. J Immunol (1986) 0.97
Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. J Immunol (1977) 0.96
T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci U S A (1992) 0.95
Potential uses of interleukin 2 in cancer therapy. Immunobiology (1986) 0.94
Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum Immunol (1997) 0.94
CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res (1995) 0.93
Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med (1979) 0.92
Treatment of aplastic anemia by bone marrow transplantation in identical twins. Blood (1980) 0.92
T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis. J Immunol (1998) 0.91
IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes. J Immunol (1988) 0.91
Models for syngeneic adoptive chemoimmunotherapy of murine leukemias. Ann N Y Acad Sci (1976) 0.91
Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy. J Immunol (1997) 0.90
Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J Exp Med (1994) 0.90
Identical-twin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst (1986) 0.89
WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res (2001) 0.89
Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. Transplantation (1982) 0.88
Immunity to the HER-2/neu oncogenic protein. Ciba Found Symp (1994) 0.88
Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine (2001) 0.88
High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults. Cancer (1981) 0.87
Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med (1982) 0.87
HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol (1998) 0.86
Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells. Cancer Res (1990) 0.86
Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2. J Immunol (1990) 0.86
Adoptive chemoimmunotherapy of cancer in animals: a review of results, principles, and problems. Ann N Y Acad Sci (1976) 0.85
Il-4 is an endogenous T cell growth factor during the immune response to a syngeneic retrovirus-induced tumor. J Immunol (1988) 0.85
Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory. J Immunol (1987) 0.85
Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology (1998) 0.84
CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood (1999) 0.84
Helper-independent CD8+ cytotoxic T lymphocytes express IL-1 receptors and require IL-1 for secretion of IL-2. J Immunol (1989) 0.82
Bone marrow transplantation for refractory acute leukemia in 34 patients with identical twins. Blood (1981) 0.81
Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. Prog Exp Tumor Res (1988) 0.81
Cure of hematologic neoplasia with transplantation of marrow from identical twins. N Engl J Med (1977) 0.81
Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression. J Immunol (1994) 0.80
Therapy of leukemia by nonimmune syngeneic spleen cells. J Immunol (1980) 0.79
Potential for specific cancer therapy with immune T lymphocytes. J Biol Response Mod (1984) 0.78
Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood (1985) 0.78
Definition of alien H-2 determinants on a Friend leukaemia by analysis of alloreactivity of CTL from primary MLC. J Immunogenet (1981) 0.78
Induction of increased graft-versus-host disease by mouse spleen cells sensitized in vitro to allogeneic tumor. Transplantation (1976) 0.78
Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein. J Immunother Emphasis Tumor Immunol (1993) 0.77
Specific adoptive immunotherapy. Prog Clin Biol Res (1989) 0.77
Intensification therapy for acute nonlymphoblastic leukemia in adults. Cancer (1983) 0.77
Combination chemotherapy for acute nonlymphoblastic leukemia in adults. Cancer Chemother Rep (1976) 0.77
Treatment of established tumor by adoptive immunotherapy with specifically immune T cells. Surv Immunol Res (1985) 0.77
Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol Immunother (1997) 0.77
CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein. J Immunother (1998) 0.77
Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins. Blood (1981) 0.77
Effector mechanisms operative in adoptive therapy of tumor-bearing animals: implications for the use of interleukin-2. J Biol Response Mod (1984) 0.76
Specific adoptive immunotherapy: experimental basis and future potential. Surv Immunol Res (1982) 0.75
Effector mechanisms by which adoptively transferred T cells promote tumor eradication. Prog Clin Biol Res (1987) 0.75
Treatment of refractory acute nonlymphocytic leukemia with a combination of pyrazofurin and cytarabine. Cancer Treat Rep (1982) 0.75
Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro. Cancer Res (1981) 0.75
Marrow transplantation for acute leukemia in man. Ann N Y Acad Sci (1976) 0.75
Recurrence of aplastic anemia following cyclophosphamide and syngeneic bone marrow transplantation: evidence for two mechanisms of graft failure. Blood (1985) 0.75
Identical twin bone marrow transplantation for hairy cell leukemia. Semin Oncol (1984) 0.75
Marrow transplantation for leukemia and aplastic anemia. Transplant Proc (1976) 0.75
Interleukin-2 administered in vivo induces the growth and augments the function of cultured T cells in vivo. J Biol Response Mod (1984) 0.75
Chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: effect of culture duration on therapeutic efficacy. J Natl Cancer Inst (1981) 0.75
Treatment of hairy-cell leukemia with chemoradiotherapy and identical-twin bone-marrow transplantation. N Engl J Med (1982) 0.75
Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression. Immunobiology (2000) 0.75
Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants. Vaccine (2005) 0.75
Adoptive immunotherapy of metastatic B16 melanoma with allogeneic immune cells sensitized to minor histocompatibility antigens. Transplantation (1985) 0.75
Distinct phenotypic expression of immunogenicity and immunosensitivity in sublines of a tumor. J Immunol (1981) 0.75
In vitro priming to tumor-associated proteins. Adv Exp Med Biol (1997) 0.75
Requirements for the generation of a Lyt-2+ T-cell proliferative response to a syngeneic tumor in the absence of L3T4+ T-cells. Cancer Res (1990) 0.75
Use of dimethylmyleran in adoptive chemoimmunotherapy of two murine leukemias. J Natl Cancer Inst (1976) 0.75